XML 19 R10.htm IDEA: XBRL DOCUMENT
v3.20.2

Organization and principal activities | 6 Months Ended
--- | ---
Jun. 30, 2020
Organization and principal activities |
Organization and Principal Activities | 1.Organization and principal activities Zai Lab Limited (the "Company") was incorporated on March 28, 2013 in the Cayman Islands as an exempted company with limited liability under the Companies Law of the Cayman Islands. The Company and its subsidiaries (collectively referred to as the "Group") are principally engaged in discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical needs in the China market and the global markets, including in the fields of oncology, infectious and autoimmune diseases. The Group’s principal operations and geographic markets are in the People’s Republic of China ("PRC" or "China"). The accompanying consolidated financial statements include the financial statements of the Company and its subsidiaries. As of June 30, 2020, the Group’s significant operating subsidiaries are as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Place of |  | Date of |  | Percentage of |  | ​
Name of company | ​ | incorporation | ​ | incorporation | ​ | ownership | ​ | Principal activities
Zai Lab (Hong Kong) Limited ​ ​ ​ ​ |  | Hong Kong S.A.R | ​ | April 29, 2013 |  | 100% | ​ | Operating company for business development and R&D activities and commercialisation of innovative medicines and device
Zai Lab (Shanghai) Co., Ltd. |  | PRC | ​ | January 6, 2014 |  | 100% | ​ | Development and commercialisation of innovative medicines and devices
Zai Lab (AUST) Pty., Ltd. |  | Australia | ​ | December 10, 2014 |  | 100% | ​ | Clinical trial activities
Zai Lab (Suzhou) Co., Ltd. |  | PRC | ​ | November 30, 2015 |  | 100% | ​ | Development and commercialisation of innovative medicines
Zai Biopharmaceutical (Suzhou) Co., Ltd. |  | PRC | ​ | June 15, 2017 |  | 100% | ​ | Development and commercialisation of innovative medicines
Zai Lab (US) LLC |  | U.S. | ​ | April 21, 2017 |  | 100% | ​ | Operating company for business development and R&D activities
Zai Lab International Trading (Shanghai) Co., Ltd. |  | PRC | ​ | November 6, 2019 |  | 100% | ​ | Commercialisation of innovative medicines and devices

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -URI http://asc.fasb.org/topic&trid=2122149 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -URI http://asc.fasb.org/topic&trid=2197479 + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration